Transformation of diploid human cells with carcinogens in vitro takes about half a year, and is much less efficient than transformation of rodent cells. 41, 42 Spontaneous carcinogenesis in humans from unknown initiation any time after birth to clinical phenotypes is estimated to take over 50 years, because the risk of spontaneous cancer rises exponentially, over 1000-fold, from negligible levels under the age of 50 to over 400 cases per million people per year at the age of 80. 14, [43] [44] [45] By contrast, classical gene mutation generates a new and final phenotype within one cell generation, as for example in bacteria.
During the long lag between initiation and clinical phenotypes, the prospective cancer cell "progresses" first through various stages of "characters that have no discernible effect at all on clinical behaviour", such as increased susceptibility to transformation by additional carcinogens, hyperplasia, altered cell morphology and aneuploidy. 1 Aneuploidy is defined as an abnormal balance of either intact chromosomes or segments of chromosomes or both. 6, 46, 84 But once the first clinical phenotypes appear, e.g., dysplasia and carcinoma in situ, progression to more malignant phenotypes, such as metastasis, abnormal morphologies, abnormal metabolism and drug-resistance, typically occurs at much higher rates. 1, 13, 47 Since the multiplicity of the malignant phenotypes is not fixed, there is no absolute definition of a cancer cell. 1 Aneuploidy stands out as the most consistent marker of malignancy. A simple aneuploidy is the earliest and most distinctive pre-neoplastic genotype. 3, 6, 17, 26, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] By contrast, a complex aneuploidy is the most typical neoplastic genotype. 53, [57] [58] [59] [62] [63] [64] The more aneuploid the cell the higher its malignancy. 3, 13, 47, 53, 62, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] According to Foulds, "In general the abnormalities of the karyotypes were of greater complexity in malignant than in non-malignant lesions…". 1 Thus, the degree of malignancy is directly proportional to the degree of aneuploidy.
The instability of the karyotype of cancer cells is also proportional to the degree of aneuploidy: It increases from undetectable rates of gains, losses and rearrangements of chromosomes per mitosis in diploid cells to a few percent in highly aneuploid cells. 28, 29, 50 Even the low degrees of aneuploidy of pre-neoplastic cells coincide with karyotype-instability. 48, 53, 60 Thus carcinogenesis is fundamentally different from mutation: It is very slow, timed from an initiating and sufficient dose of carcinogen. It is associated with aneuploidy from its initiation. After initiation, it generates abnormal phenotypes spontaneously, i.e. without further carcinogens, including eventually cancer-specific phenotypes. These phenotypes are unstable and thus typically progress from bad to worse, 1 or shift from drug-sensitive to drug-resistant, or from one morphological grade or metabolic state to another-unlike conventional gene mutations. 2, 4, 11, 12 
MECHANISMS OF CARCINOGENESIS
Despite over a century of cancer research, the mechanism of carcinogenesis is still a matter of debate, primarily between two schools of thought. 33, [76] [77] [78] [79] [80] One school holds that cancer-specific phenotypes are the result of multiple, specific gene mutations, which either generate dominant oncogenes, or inactivate recessive tumor suppressor genes. 2, 77, [81] [82] [83] [84] [85] [86] The competing school holds that cancerspecific phenotypes are the results of the thousands of normal genes whose dosage is altered by reassortments of the corresponding chromosomes or aneuploidy. 6, 35, 76 
ARE THE MULTIPLE STEPS OF CARCINOGENESIS MULTIPLE MUTATIONS?
Since the risk of mutations increases linearly with age, but the risk of cancer increases exponentially, over 1000-fold, the proponents of the mutation hypothesis postulate that between 4 and 7 mutations are necessary for carcinogenesis. 14, 40, [43] [44] [45] Only complete sets of these genes are thought to cause cancer. 14, 45, 83 However, the problem of where the huge number of random mutations would come from that is necessary to mutate 4-7 specific genes has not been solved.
Based on the normal, spontaneous gene mutation rate of about 10 -6 per mitosis, 87 only 1 in 10 24 -10 42 human cells would ever become cancer cells. 6, 31, 88, 89 Since humans consist of 10 14 cells, 14 only 1 in 10 10 -10 28 humans would ever get cancer. This number would be even lower, if the mutation rates of the recessive cancer genes, as for example the hypothetical tumor suppressor genes, are squared. In other words cancer would hardly exist.
To solve this problem, the proponents of the mutation hypothesis have postulated that prior to mutation of prospective cancer genes, another class of cellular genes must be mutated to mutator genes, which in turn would mutate prospective cancer genes to real cancer genes. 3, 32, 88, 90, 91 The presence of such mutator genes, early in carcinogenesis, could then also explain the spontaneous, or carcinogenindependent, progression of initiated cells to cancer cells. However, in the words of Breslow and Goldsby, "a mutator gene really begs the question … one is left with the problem of accounting for such a high frequency of mutator genes." 92 But, the origin of multiple specific mutations in the same cell is not the only problem of the mutation hypothesis. According to Cairns' Cancer, Science and Society, "One of the problems is that mutations lead to loss of function rather than creation of new function." 14 Creation of cancer-specific phenotypes is particularly hard to reconcile with mutation because of their multiplicity and extraordinary complexity. Even ardent proponents of the mutation hypothesis acknowledge this problem: "our understanding of the biology of these tumors will become a phenomenology of unlimited complexity." 93 Thus, how could a prospective cancer cell ever survive the "loss of function" that is associated with the high mutation rates, which are necessary to generate the 4-7 specific mutations and possibly further "unlimited complexity" of cancer cells? Since the probability that any one of the 35,000 human genes 191 is mutated is 1:35,000, but the probability that 4-7 genes are mutated is only 1:(35,000) [4] [5] [6] [7] , virtually all genes of a prospective cancer cell would have to be mutated before it could turn into a cancer cell. Suppose then a cell with a mutator gene has suffered 1000 random mutations, its chance to become transformed into a cancer cell by 4 specific mutations is only 1 in 1.5 million, and after it has suffered 5000 random mutations, this chance is still only 1 in 2400. But how could any cell carry out the many cell cycles, that set apart initiation from completion of carcinogenesis, in the face of so many mutations?
In view of these questions, we have reexamined the merits of the mutation hypothesis by testing whether it could predict a list of 14 basic facts of carcinogenesis, that are summarized in Table 1 (next page). Since the hypothesis fails to predict any of these facts, we conclude that it is not a satisfactory explanation of carcinogenesis.
ARE THE MULTIPLE STEPS OF CARCINOGENESIS MULTIPLE ANEUPLOIDIZATIONS?
In an effort to find an alternative cancer hypothesis, we decided to search the literature for facts that are neglected by the mutation hypothesis. Surprisingly, we did not have to look very long to find aneuploidy.
But despite a preponderance of evidence in support of the hypothesis that aneuploidy may cause cancer; there is currently a strong bias against this hypothesis. 132 In the following we describe:
1. the evidence for aneuploidy; 2. the current bias against the aneuploidy hypothesis; and 3. a unifying hypothesis that answers the scientific objections that have been made against aneuploidy, and that explains all facts of carcinogenesis.
The Evidence for Aneuploidy as the Cause of Cancer.
The following collection of facts lends correlative, functional and conceptual support to the aneuploidy-cancer hypothesis:
Aneuploidy is ubiquitous in solid cancer. 25, 62, 67, 133 This is correlative proof for causation. Aneuploidy is also found in about half of all leukemias, 134,135 the diploid half being hyperplasias. 6 In contrast to the diploid leukemias, the cells of the aneuploid leukemias are dedifferentiated, immortal, and able to mutate to drug-resistance at high rates, just like solid cancers. 12, 136 The degree of malignancy is proportional to the degree of aneuploidy of a cancer: The more aneuploid the karyotype the more malignant the cancer (see above). 3, 13, 47, 59, 60, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] 137 Aneuploidy inevitably causes highly abnormal and complex phenotypes in lower and higher eukaryotes by altering the dosages 2 Cancer-phenotypes are determined by cancerBut, about half of all solid cancers of any kind lack hypothetical cancer genes or oncospecific mutations.
genes. 31, 89, [97] [98] [99] [100] 193 In other words oncogenes do "not impart distinct clinical properties on most tumors." 99 Yet, "phenocopies" of known oncogenes are said to cause those cancers in which known oncogenes can not be found. 97 Since only 4-7 gene mutations are thought to be But, thousands of genes are abnormally expressed in cancer cells, [114] [115] [116] "the sine qua necessary for carcinogenesis, 14, 83, 84, 123 only non of malignant transformation". 4 small numbers of genes should be abnormally expressed in cancer cells.
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Inheritance of 3-6, of the 4-7 mutations thought to But, the incidence of solid cancer at young age is negligible, 14, [43] [44] [45] ; For key, see Table  to be necessary for carcinogenesis, predicts solid 2(#6) cancer at very young age from a single, somatic mutation in any of billions of susceptible cells.
9
In view of the low rates of spontaneous gene But, "mutator genes" are only detectable in a small minority of cancers. 24,29,31,32,124-126 mutation, 10 -6 per mitosis (see text), mutator genes are And the gene mutation rates of many cancers are normal. 127, 128 Moreover, mutator necessary for carcinogenesis-even for the genes are typically only detectable at late stages of carcinogenesis, suggesting that they spontaneous "progression" of "initiated" are consequences of neoplastic development. 128 ,129 cells to cancer cells.
10
The majority of cancers, ie. those without mutator But, all cancer cells are, more or less, genetically unstable. 1,3,11,12,48,60 genes, are genetically stable, like conventional mutations.
11
Genetic instability of cancer cells is proportional to Instead, genetic instability of cancers is proportional to the degree of aneuploidy (see the presence and nature of mutator genes. text). 28, 50, 130 12 Congenital mutator genes increase the risk of all cancers. But, the mutator gene of Xeroderma Pigmentosum, which is postulated to cause skin cancer, does not increase the risk of non-skin cancers. 131 ; For key, see Table 2(#1) 13 Certain mutant phenotypes of cancer cells, such as Yet, despite 3 billion years of mutation, none of these desirable phenotypes are ever immortality, resistance to singular or even multiple found in normal organisms! For key, see Table 2 (#6) cytotoxic drugs, and resistance to cytotoxic viruses, should be highly attractive for normal animals and humans. of thousands of normal genes. This was first demonstrated in doublyfertilized sea urchins 138 and has since been confirmed in aneuploid drosophila, 139 plants, 140 yeast, 141, 142 mice, 143 and humans with Down's syndrome and other congenital aneusomies. [144] [145] [146] The probable basis of the abnormal phenotypes of aneuploidy is the abnormal dosage and expression of thousands of normal genes. [146] [147] [148] 152 The power of aneuploidy to generate abnormal phenotypes becomes immediately obvious if one compares the cell to a car factory and chromosomes to assembly lines. Unbalance these assembly lines and you get highly abnormal cars from entirely normal parts, e.g., cars with five wheels, no brakes, red headlights, etc. Most of these aneuploid cells would be non-functional, but a few would be able to out-compete normal cells in the permissive habitat of the body. The analogy also explains why a gene mutation, an altered assembly line worker in our analogy, is unlikely to generate the new properties of cancer cells: Any "activating" mutation 82 would be buffered by the un-mutated genes of the assembly line working at normal rates. 149 Likewise, most inactivating mutations would be buffered, since nearly all enzymes work in the cell at only a very small fraction of their capacity. 150, 151 Only very rare null mutations would bring the assembly line to a halt, in which case the second allele is usually sufficient to maintain normal cell function. 152 However, if both assembly lines cease to work by mutations, the resulting cell is more likely to die than to develop the highly complex, new phenotypes of cancer cells (see above). Thus, aneuploidy is the simplest explanation for the many dominant and abnormal phenotypes of cancer cells. 152 Aneuploidy has even been proposed as a cause of cancer over 100 years ago, first by von Hansemann because of suggestive evidence for its presence in epithelial cancer 153 (the exact chromosome number of humans was only determined in 1956), and then by Boveri based on the discovery that aneuploidy can cause abnormal phenotypes in sea urchin embryos. 138, 154 The first experimental proof was obtained in 1930 by Winge who showed that the skin cancers induced in mice treated with tar were indeed aneuploid. 137 2. The Current Bias Against Aneuploidy. In view of a series of new genetic and cytogenetic discoveries (see below), above all the discovery of heterogeneous and thus apparently unspecific karyotypes in most cancers, the original aneuploidy hypothesis was abandoned in the 1960s and 1970s. The resulting bias against the aneuploidycancer hypothesis is now based on the following arguments:
1) Aneuploidy is seen as a consequence or epiphenomenon of cancer. In the 1960s and 1970s it was discovered (a) that most cancers Figure 1 . Multistep carcinogenesis via aneuploidizations. The vertical banded bars are chromosomes, the squares are normal diploid, and the circles are abnormal, aneuploid cells. Our model proposes that various specific chromosome assortments or aneusomies cause cancer. According to this model, carcinogenesis is initiated by a random aneuploidy, which is induced either by a carcinogen or spontaneously. Since aneuploidy unbalances mitosis proteins and the many enzymes that synthesize and maintain chromosomes, it renders chromosome segregation error-prone. The resulting karyotype instability sets off a chain reaction of aneuploidizations that generate ever more abnormal chromosome assortments, including non-viable and eventually cancer-specific chromosome assortments. The cancer-specific phenotypes-abnormal metabolism and morphology, invasiveness, drug-resistance, immortality and metastasis-are generated by the abnormal dosages of thousands of normal genes. Since aneuploid chromosome assortments are reversible, cancer-specific phenotypes such as drug-resistance can get lost at the same rates at which they are generated; likewise malignancy of non-tumorigenic cancer-normal-cell hybrids is recovered by loss of chromosomes. The model predicts the heterogeneous phenotypes and karyotypes of cancer cells as mixtures of selectively advantageous, cancer-specific and selectively neutral, random chromosome assortments. The model further predicts that both malignancy and karyotype instability are proportional to the degrees of aneuploidy, which is consistent with the literature (see text).
are clonal, 1, 3, 4, 14, 15 and (b) that their karyotypes are heterogeneous -a "confusing plethora" 155 -and thus non-clonal. 1, 13, 24, 62, 63, 119, 156 Since these facts were incompatible with the expectation, that a specific aneuploidy would cause a specific cancer, it was concluded that aneuploidy must be a consequence, rather than a cause of cancer. 13, 25, 62, 79, 119, 131, 157, 158 2) Aneuploidy unknown as source of neoplastic phenotypes. Aneuploidy is also disregarded as a cause of cancer, because phenotype alteration by aneuploidy is simply unknown in cancer research. By contrast, phenotype alteration by gene mutation is canonical knowledge. For example, Foulds writes in Neoplastic Development in 1975, "The interpretations of the observations [of aneuploidy] on dysplasia and carcinoma in situ and on progression in these lesions …are still controversial." 1 Cairns writes in 1981 in Nature, "the observed changes in karyotype could … be trivial secondary events that occur after the rate limiting steps of carcinogenesis have been completed." 131 Cancer Biology, by Ruddon, says about "aneuploidy" in 1987, "Although the more subtle changes in the genome-namely point mutations, gene deletions, and gene rearrangements-may be associated with initiation of the malignant transformation process, gross changes in the number of chromosomes usually occur as tumors progress to malignancy." 13 Mitelman et al. state in 1997, "the pathogenic significance of such abnormalities [aneuploidy] is totally unknown." 158 Orr-Weaver and Weinberg point out in 1998 "Aneuploidy has long been speculated to be causally involved in tumorigenesis, but its importance has not been demonstrated." 159 An editorial in Science comments in 1999 that it is "still unresolved…whether an increase in ploidy contributes to, or is a consequence of, tumor development." 148 Zimonjic et al. deplore in 2001 that aneuploidy, "confounds attempts to determine the precise cohort of genetic changes that are required for the transformation of normal human cells to a tumorigenic state...". 160 In line with this disregard for aneuploidy, the identification of suspected cancer genes and the analysis of the multiple steps of carcinogenesis are now routinely conducted in highly aneuploid cell lines, above all the mouse 3T3 and C3H 10T1/2 lines, which are assumed to be not tumorigenic because they resemble normal diploid fibroblasts morphologically. 2, 82, 84, 161 However, the relevance of results obtained with aneuploid cell lines to carcinogenesis must be called into question, because most, if not all of them are tumorigenic irrespective of their morphology. 162 
4
Even after a sufficient dose of carcinogen, cancer does not appear for a long time-namely years Refs. 5, 13, 14, 25, [38] [39] [40] 64 to decades-because cancer-specific aneuploidies must evolve from random aneuploidizations.
5
Cancer-specific aneuploidies or aneusomies determine cancer-specific phenotypes. Refs. 13, 25, 53, 64 6 Cancer typically appears only at advanced age (age bias), because aneuploidy is not heritable, 183 Refs. 5, 14, [43] [44] [45] ; Key for 
15
Clonal mutations in cancers derive from pre-neoplastic aneuploidy and non-clonal mutations Ref. 50 ; See Table 1 from neoplastic aneuploidy.
16
"Immortality" of aneuploid cells derives from variants that evade lethal mutations or toxins by Refs. 6,11,12,189 reassorting chromosomes.
17
Transient suppression of tumorigenicity via fusion of cancer cells with normal cells by unbalancing Refs. 6, 119, 190 ; See text cancer-specific chromosome assortments. Tumorigenicity re-emerges via loss of chromosomes (Fig. 1) .
18
Abnormal expression of hundreds or thousands of normal but aneuploid genes -the "sine qua non Refs. 114-116 of malignant transformation". 4 transformation with hypothetical cancer genes or with carcinogens. 164 Moreover, complete chromosome balances of multiple cells of human cancers, which are necessary to distinguish specific from unspecific aneuploidy, are not even reported in the recent literature, based on our experience. As a result of this bias, modern textbooks of biology do not even mention aneuploidy in the context of carcinogenesis. 84, 85, 170 3) Aneuploidy said to be not necessary for cancer. The existence of presumably diploid cancers is cited as an argument that aneuploidy is not necessary for cancer. However, each of these cases fails to provide adequate documentation either for diploidy or for malignancy of the respective tumors. 8, 33, 76, 79, 80, 165, 166 For example, Zimonjic et al. state in 2001 that, "a limited set of genes suffices to induce human cell transformation… [and] that widespread genomic changes involving large arrays of cellular genes [alias aneuploidy] are not required …". 160 But not even one in over 46 of their reportedly diploid, human tumor cells proved to be diploid in a subsequent cytogenetic analysis conducted by us. 77 Further, Loeb et al. exclude aneuploidy as a cause of cancer-"it is neither a clonal marker nor an initial event"-based on the normal karyotype of "a premalignant condition". 91 4) Aneuploidy said to be not sufficient for cancer. Since some hybrids of normal and cancer cells are not tumorigenic, it has been argued that, unless certain normal genes are mutated, aneuploidy is not sufficient for carcinogenesis. 2, 4, 119 However, all non-tumorigenic hybrids readily revert to tumorigenicity by spontaneous loss of chromosomes (see below and Fig. 1) . 2, 4, 119 This argument also ignores that the vast majority of such hybrids, including all the mouse lymphocyte-myeloma hybrids or hybridomas, are immortal and tumorigenic a priori. 2, 6, 84, 167 5) Aneuploidy interpreted as support for the gene mutation hypothesis. Recently aneuploidy has been reconsidered as a cause of cancer, if only as a mechanism to alter the dosage of hypothetical cancer genes or to generate new ones by mutation. For example, Lengauer et al. proposed in 1997 that aneuploidy may "select for gains of chromosomes containing activated oncogenes and for losses of chromosomes containing tumour-suppressor genes", 29 and, in a subsequent study, that it can "accelerate the acquisition of growth promoting mutations", 48 possibly by rearranging genes at breakpoints of rearranged chromosomes. 30, 158 In 2002, Weinberg et al. also proposed "that aneuploidy facilitates the acquisition of the genetic alterations that lead to cancer." 168 A recent review in Nature simply reduces Boveri's chromosomal theory to the current oncogene theory of cancer, "if we substitute the word 'gene' for 'chromosome', this vision clearly predicted the Nobel Prize-winning discovery of cellular protooncogenes by Harold Varmus and Mike Bishop in the 1970s…". 169 Thus, for all those who have recently been looking for alternative causes of cancer, aneuploidy proved to be, at best, a diamond in the rough. 33, 79, 80 3. A Unifying Hypothesis-Multistep Carcinogenesis via a Chain Reaction of Aneuploidizations. Intrigued by the enormous mutagenic potential of aneuploidy, its ubiquity in cancer and its proportionality with the degree of malignancy, we took up the challenge to develop an aneuploidy hypothesis, that:
1. would explain the origin of aneuploidy in cancer; 2. the spontaneous but characteristically slow evolution of an initiated cell to a cancer cell; and 3. how non-clonal and unstable karyotypes cause cancer.
We think the model, that carcinogenesis results from a chain reaction of aneuploidizations, meets this challenge (see Fig. 1 ).
According to our model the various phenotypes of cancer are consequences of cancer-specific aneuploidies, which alter the dosages of thousands of normal genes. 64 These cancer-specific aneuploidies are products of a stepwise karyotype evolution that is initiated by a random aneuploidy. The initiating aneuploidy is caused either by a physical or chemical carcinogen, or is spontaneous. 6 Since aneuploidy unbalances, via the corresponding genes, numerous, long-established teams of synergistic mitosis-proteins, and even the numbers of centrosomes, [171] [172] [173] [174] it renders chromosome segregation error-prone. 6, 152, 175 Thus aneuploidy generates ever-new karyotypes autocatalyticallylike a chemical chain-reaction. Additional carcinogens and tumor promoters 2 can accelerate this evolution hetero-catalytically. 176, 177, 192 Most of the randomly generated chromosome assortments would be lethal or less viable than normal ones, but some would be able to out-compete normal cells in the permissive habitat of the body and would thus be able to cause cancer. Since most random changes of chromosomes are unlikely to generate chromosome assortments that out-perform normal ones, the appearance of a cancer-specific aneuploidy is a rare and most probably a multistep event-analogous to the evolution of a new species. Indeed, carcinogenesis and phylogenesis both depend on alterations of chromosome numbers and structures. This is the reason, why it typically takes a long time to develop cancer. The end-product of this multistep evolution would be a maximally aneuploid or near-triploid, and thus also a maximally unstable and hence adaptable karyotype, 152 which is the karyotype of the most malignant cancer cells. 6, 62, 67, 178 The inherent instability of highly aneuploid karyotypes explains the notorious heterogeneity or non-clonality of the karyotypes of clonal cancers as superpositions of selectively advantageous, cancerspecific and selectively neutral, random chromosome assortments. Thus cancer is clonal for aneuploidy and for various specific aneusomies, but not for a unique karyotype. 64 Since aneuploidy also unbalances the many teams of DNA synthesis-and DNA maintenance-genes, 84, 179 and the genes that maintain nucleotide pools, 180 aneuploidy also destabilizes the structure of the chromosomes and genes of cancer cells 50 -a state that is collectively called "genetic instability". 3, 33 According to our model many gene mutations of cancer cells would then be consequences of aneuploidy. Thus, our model predicts that malignancy, karyotypic and genetic instability are all proportional to the degrees of aneuploidy, which is consistent with the literature 50 (see Table 1, Table 2 and Fig. 1) .
Our model also predicts that aneuploid chromosome assortments-but not rearrangments-are reversible. In support of this, some cancer-specific phenotypes such as drug-resistance can get lost at the same rates at which they are generated, 11, 12 and malignancy of non-tumorigenic cancer-normal-cell hybrids is recovered by loss of chromosomes (Fig. 1) . 62, 119 Our model is not only relevant to the origin of cancer from normal cells but also from hyperplasias with balanced karyotypes that carry a higher than normal risk of aneuploidization, as for example Barrett's esophagus 61 or the chronic phase of myeloid leukemia with the Philadelphia chromosome. 4, 6 However, our model is not relevant to the origin of diploid hyperplasia. For example, UVlight causes benign,hyperplastic papillomas in a small fraction of the mice in which it causes carcinomas-compatible with an aneuploidyindepdent mechanism. 192 Our model of carcinogenesis confirms and extends the one proposed by Nowell in 1976. 3 Like Nowell, we propose that the steps of progression of an initiated cell are aneuploidizations, although Nowell left open whether aneuploidy or gene mutation were causing cancer, "the genetic-versus-epigenetic debate". But in contrast to Nowell's model, which holds that "It is certainly clear that visible alterations in chromosome structure are not essential to the initial change", our model proposes that initiation is a random aneuploidy induced by a carcinogen, along the lines of Boveri's hypothesis. Most importantly our hypothesis explains the origin of "genetic instability" by autocatalytic karyotype variation of aneuploid cells. As observed by Nowell, "this important characteristic has not been satisfactorily explained." 3 To prove our model, we have tested 18 of its predictions either by conducting new experiments or by selecting predicted experimental results from the large literature on cancer. It is shown in Table 2 , that the literature, including our own work, does indeed support all of these 18 predictions made by the aneuploidy-cancer hypothesis.
Thus the hypothesis, that multistep carcinogenesis is a chain reaction of aneuploidizations, can explain and predict all facts of carcinogenesis, particularly those that are paradoxical in view of the gene mutation hypothesis (Table 1) .
RELEVANCE OF THE ANEUPLOIDY HYPOTHESIS FOR THE CONTROL OF CANCER
The chromosome hypothesis promises several benefits for the control of cancer. For example, eliminating from food and drugs substances that cause aneuploidy could prevent cancer. Identifying pre-cancerous cells in biopsies based on aneuploidy could revolutionize cancer therapy by eliminating affected tissues before they turn malignant. Even the treatment of clinical cancer could possibly be improved based on the risks that particular chromosome combinations may present. In principle this is already being proposed now based on genome-wide transcription profiles derived from micro-arrays of thousands of cellular genes. [114] [115] [116] 
